---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027756"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:59:56.606864+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine Q2 net loss $42.4M; cash $221.1M; Cimeio partnership

## Summary
- Net loss of $42.4M for Q2 2023 vs $29.3M in Q2 2022; R&D expenses $34.6M (+83% YoY).
- Cash, equivalents and investments $221.1M as of June 30, 2023; runway into 2025.
- Entered research collaboration with Cimeio Therapeutics to develop shielded cell therapies for genetic diseases.
- PM359 for chronic granulomatous disease advancing; IND-enabling studies expected in 2023.
- First IND filing anticipated as early as 2024; additional filings in 2025.

## SEC filing metadata
- accession: 0001628280-23-027756
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/0001628280-23-027756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/prme-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027756
- JSON: https://secwatch.observer/filing/0001628280-23-027756.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027756.txt

## Key facts
- Earnings Releases
  Prime Medicine, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $42.4 million for the three months ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss was $42.4 million for the three months ended June 30, 2023
  - Result: reported results
  source text: Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828023027756/0001628280-23-027756-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.